Unicycive Therapeutics Presents OLC Review Update With March 25, 2027 FDA Target Action DatePUBT·Nov 12, 2026 at 05:09 PMUNCY-2.47%
Unicycive Therapeutics tumbles 8% during regular tradingMarket Movers·Nov 5, 2026 at 03:41 PMUNCY-2.47%
Unicycive Therapeutics (UNCY) Projected to Release Quarterly Earnings on WednesdayMarket Beat·Nov 4, 2026 at 02:42 PMUNCY-2.47%
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference | UNCY Stock NewsStockTitan·Nov 4, 2026 at 04:05 AMUNCY-2.47%
Unicycive Therapeutics presents OLC regulatory update with March 25, 2027 FDA decision targetPUBT·Nov 2, 2026 at 08:52 PMUNCY-2.47%
Unicycive Therapeutics hit a new 52-week low in pre-market trading, currently at $3.29, down about 12%Market Movers·Nov 2, 2026 at 09:03 AMUNCY-2.47%
Unicycive Therapeutics consensus price target decreased by 10.97% to $28.97MSN·Nov 2, 2026 at 07:34 AMUNCY-2.47%
Unicycive Grants Director Meredith Manning 27,000 Stock OptionsPUBT·Oct 29, 2026 at 08:46 PMUNCY-2.47%
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuitprnewswire·Oct 24, 2026 at 02:28 PMUNCY-2.47%
Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Down 1.3% - Should You Sell?Market Beat·Oct 24, 2026 at 05:00 AMUNCY-2.47%
What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadlineprnewswire·Oct 23, 2026 at 06:11 PMUNCY-2.47%
